---
title: "Shanghai Henlius Biotech’s HLX99 Receives FDA Approval for ALS Treatment"
date: "2025-02-10 18:09:41"
summary: "Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart PortfolioShanghai Henlius Biotech, Inc. Class H..."
categories:
  - "tipranks_announcements"
lang:
  - "en"
translations:
  - "en"
tags:
  - "tipranks_announcements"
menu: ""
thumbnail: "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1561815367-1-750x406.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

### Maximize Your Portfolio with Data Driven Insights:

* Leverage the power of [TipRanks' Smart Score](https://www.tipranks.com/screener/top-smart-score-stocks), a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
* Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  [Your Smart Portfolio](https://www.tipranks.com/smart-portfolio/holdings)

Shanghai Henlius Biotech, Inc. Class H ( [(HK:2696)](https://www.tipranks.com/stocks/hk:2696) ) just unveiled an announcement.

Shanghai Henlius Biotech, Inc. announced that its investigational new drug, HLX99, has received approval from the United States Food and Drug Administration for the treatment of amyotrophic lateral sclerosis (ALS). This approval marks a significant milestone for the company’s research and development efforts in creating innovative treatments for neurodegenerative diseases. With ALS drugs generating global sales of approximately $417 million in 2023, HLX99’s FDA approval could enhance the company’s positioning in the pharmaceutical market, although commercialization success is not guaranteed.

**More about Shanghai Henlius Biotech, Inc. Class H**

Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development of biopharmaceutical products. The company specializes in creating innovative therapies for various diseases, with a particular emphasis on treating neurodegenerative conditions.

**YTD Price Performance:** -15.40%

**Average Trading Volume:** 761,561

**Technical Sentiment Consensus Rating:** Hold

**Current Market Cap:** HK$10.9B

For a thorough assessment of 2696 stock, go to [TipRanks’ Stock Analysis page](https://www.tipranks.com/stocks/hk:2696/stock-analysis).

Trending Articles:
------------------

* [Here’s How Palantir (PLTR) Makes a Million Bucks Through a “Revolving Door”](https://www.tipranks.com/news/heres-how-palantir-pltr-makes-a-million-bucks-through-revolving-door)
* [‘Don’t Worry,’ Says Top Investor About Apple Stock](https://www.tipranks.com/news/dont-worry-says-top-investor-about-apple-stock)
* [Upcoming Stock Splits This Week (February 10 to February 14) – Stay Invested](https://www.tipranks.com/news/upcoming-stock-splits-this-week-february-10-to-february-14-stay-invested)

[tipranks_announcements](https://www.tipranks.com/news/company-announcements/shanghai-henlius-biotechs-hlx99-receives-fda-approval-for-als-treatment)
